Stockscreener 앱 받기
2.3403
1.84%
-0.0697
전일 마감가:
$2.41
열려 있는:
$2.38
하루 거래량:
4,712
Relative Volume:
0.17
시가총액:
$72.87M
수익:
$300.00K
순이익/손실:
$-40.16M
주가수익비율:
-1.7765
EPS:
-1.3174
순현금흐름:
$-42.36M
1주 성능:
+2.85%
1개월 성능:
-0.18%
6개월 성능:
-5.75%
1년 성능:
-22.44%
1일 변동 폭
$2.38
$2.39
1주일 범위
$2.30
$2.4352
52주 변동 폭
$2.09
$3.61
Xbiotech Inc Stock (XBIT) Company Profile
명칭
Xbiotech Inc
전화
512-386-2900
주소
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.39 | 70.12M | 300.00K | -40.16M | -42.36M | -1.3174 |
VRTX
Vertex Pharmaceuticals Inc
|
520.02 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.50 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.32 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.28 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
188.90 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-14 | 개시 | Piper Jaffray | Overweight |
| 2017-04-21 | 다운그레이드 | Noble Financial | Buy → Hold |
| 2016-06-28 | 재확인 | Noble Financial | Buy |
Xbiotech Inc 주식(XBIT)의 최신 뉴스
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - Yahoo Finance UK
XBiotech Inc. (XBIT) Holds Near Support Amidst Minor DeclinesDescending Triangle - newsline.com
XBIT Should I Buy - Intellectia AI
XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update - Ad-hoc-news.de
XBiotech Inc. (XBIT) Slips 2.27% as Stock Tests Key Support LevelsMotive Wave - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher, Approaching Key Resistance at $2.56Trading Ideas - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher on Modest Volume, Tests Resistance Near $2.58Composite Profile - The Legal Advocate
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
XBiotech stock (US9840001002): Clinical-stage biotech stays in focus - AD HOC NEWS
XBiotech: Q1 Earnings Snapshot - Stamford Advocate
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XBiotech (NASDAQ: XBIT) trims Q1 2026 loss, holds $115.5M cash and cuts R&D spend - Stock Titan
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar - TipRanks
TradingKey - TradingKey
Number of shareholders of XBiotech, Inc. – FWB:4XB - TradingView
XBiotech (XBIT) Projected to Post Earnings on Tuesday - MarketBeat
XBIT (XBiotech) reports zero Q1 2020 EPS missing estimates, shares dip 0.78 percent amid investor concern.Post Announcement - newser.com
XBiotech Inc. 2025 Executive Compensation, Board Structure, and Shareholder Ownership Overview - Minichart
Executive pay and governance detailed in XBiotech (NASDAQ: XBIT) 10-K/A - Stock Titan
XBIT Stock: A Comprehensive Guide to XBiotech Inc. - Bitget
XBIT (XBiotech) posts 100 percent Q1 2020 EPS miss, falls 0.79 percent on soft investor sentiment.Trader Community Insights - newser.com
XBIT (XBiotech Inc.) reports 100 percent Q1 2020 EPS miss, while shares notch mild gains on upbeat investor sentiment.Dividend Cut Risk - Xã Thanh Hà
XBiotech (XBIT) Stock: Price Action Overview (Smart Money Active) 2026-04-18Verified Analyst Reports - Xã Vĩnh Công
Short Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 21.3% - MarketBeat
Aug PostEarnings: Is XBiotech Inc part of any major index2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Xbiotech Inc (XBIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.85%
자본화:
|
볼륨(24시간):